Forecast: Cardiovascular System Medicine Sales in South Korea

The forecasted cardiovascular system medicine sales in South Korea show a consistent year-on-year growth from 2024 to 2028. The data reveals an upward trend in per capita sales from $92.1 in 2024 to $103.7 in 2028. The year-on-year variation percentage for the respective years shows steady growth:

• From 2024 to 2025: approximately 3.1%
• From 2025 to 2026: approximately 3.1%
• From 2026 to 2027: approximately 3.0%
• From 2027 to 2028: approximately 2.9%

When observing the longer-term trend, the compound annual growth rate (CAGR) over this forecasted five-year period indicates an average annual increase of around 3.0%.

In 2023, the actual sales per capita stood slightly under the 92.1 USD mark of 2024, suggesting a well-established upward momentum as we step into the forecasted period.

Future trends to watch for include potential advancements in cardiovascular treatment technologies and shifts in healthcare policies that may impact market dynamics. Additionally, an aging population and an increasing prevalence of cardiovascular diseases could further drive demand in the coming years, potentially altering forecasted growth rates.